Stimulants for depression: On the up and up?
@article{Malhi2016StimulantsFD, title={Stimulants for depression: On the up and up?}, author={Gin S. Malhi and Yulisha Byrow and Darryl L Bassett and Philip Boyce and Malcolm Hopwood and William Lyndon and Roger T. Mulder and Richard J. Porter and Ajeet B Singh and Greg Murray}, journal={Australian \& New Zealand Journal of Psychiatry}, year={2016}, volume={50}, pages={203 - 207} }
The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness. The current article describes the role of stimulants in treating depression – specifically their risks and benefits and their potential use alongside antidepressants. Clinically, the rapid amelioration of depressive symptoms with traditional…
31 Citations
Why do stimulants not work in typical depression?
- PsychologyThe Australian and New Zealand journal of psychiatry
- 2017
Arousal, a dimension included in the Research Domain Criteria project of the National Institute of Mental Health, can be assessed with an electroencephalography-based algorithm and is a promising biomarker to identify subgroups of patients, which might respond to stimulants.
The use of stimulants in depression: Results from a self-controlled register study
- Psychology, MedicineThe Australian and New Zealand journal of psychiatry
- 2020
Methylphenidate was associated with a 54% reduction in incidents of self-harm or suicide attempts, indicating that methylphenidate may potentially be useful in patients with depression with suicidal- or self-harming behaviour.
Psychostimulants as antidepressants: Their nuanced role?
- PsychologyThe Australian and New Zealand journal of psychiatry
- 2022
While effectively the 'first antidepressants', the psychostimulants are rarely prescribed as antidepressant drugs seemingly in light of their judged low effectiveness, side effects, tolerance as well…
The use of antidepressants in oncology: a review and practical tips for oncologists
- Psychology, MedicineAnnals of oncology : official journal of the European Society for Medical Oncology
- 2018
ADs are a relatively safe and effective treatment for more severe major depression in cancer patients and more research is urgently needed regarding the efficacy of ADs in different cancer types and cancer settings, their interactions with anticancer agents and their additive benefit when integrated with psychosocial interventions.
Use of Stimulants for ADHD and TBI in Veterans
- Psychology, MedicineVeteran Psychiatry in the US
- 2019
The authors review the most common psychiatric conditions for which stimulants may be indicated in veterans as well as tips for successful prescribing practices, monitoring ongoing use, and potential pitfalls and contraindications.
The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities
- Psychology, BiologyNeuroscience & Biobehavioral Reviews
- 2018
Preclinical Models for Assessment of Antidepressant Abuse Potential
- Psychology, BiologyCurrent Sexual Health Reports
- 2017
Increasing extracellular dopamine may both increase antidepressant efficacy and reduce sexual dysfunction, but it increases abuse potential.
Treatment resistant depression
- PsychologyKetamine for Treatment-Resistant Depression
- 2021
It is crucial that researchers and clinicians have a thorough understanding of treatment-resistant depression (TRD) and its potential treatments.
Psychotropic and neurological medication effects on mitochondrial complex I and IV in rodent models
- Psychology, BiologyEuropean Neuropsychopharmacology
- 2019
The Efficacy and Safety of Concomitant Psychotropic Medication and Electroconvulsive Therapy (ECT)
- PsychologyCNS Drugs
- 2020
This review evaluates the impact of a variety of psychotropic medications often used in conjunction with ECT and examines strategies to optimize their management.
References
SHOWING 1-10 OF 30 REFERENCES
[Psychostimulants in the treatment of depression].
- Psychology, MedicinePresse medicale
- 2013
A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder.
- Psychology, MedicineThe Journal of clinical psychiatry
- 2014
The promising results of 1 recent lisdexamfetamine RCT, when considered in the context of the deleterious effect of subsyndromal depression, suggest consideration of dopaminergic medications in treatment-refractory unipolar or bipolar depression when modafinil is cost prohibitive or otherwise contraindicated.
An open study of methylphenidate in bipolar depression.
- Psychology, MedicineBipolar disorders
- 2000
In this brief, open study, methylphenidate was effective and relatively safe in depressed bipolar subjects and was shown to reduce manic behavior.
Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials
- Psychology, MedicineNordic journal of psychiatry
- 2013
Clearly larger well designed placebo-controlled studies with longer follow-up accompanied by evaluations of tolerance/dependence are warranted before psychostimulants can be recommended in routine clinical practice for the treatment of MDD.
The role of stimulants in late-life depression.
- Psychology, MedicineThe American journal of psychiatry
- 2015
The authors found that the combination treatment accelerated response and increased the remission rate, and the differences were statistically significant and clinically meaningful.
The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives
- Psychology, MedicinePsychotherapy and Psychosomatics
- 2014
The success of switching to a different antidepressant following a first-line agent is supported by evidence, but there is limited evidence for effective combination strategies.
Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial
- PsychologyInternational clinical psychopharmacology
- 2015
LDX was well tolerated and was not associated with any serious adverse events, but there was one case of suspected misuse, which may have limited the detection of important drug–placebo differences.
Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study
- Medicine, PsychologyJournal of clinical psychopharmacology
- 2007
Primary measures suggested modafinil may have provided benefit for symptoms of excessive sleepiness in patients with depression, and mixed-model analysis of the change in the Epworth Sleepiness Scale showed no difference between modaf inil- and placebo-treated patients.
Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
- PsychologyThe Journal of clinical psychiatry
- 2013
Modafinil is an effective augmentation strategy for acute depressive episodes, including for symptoms of fatigue, in both unipolar and bipolar disorders.
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
- Psychology, MedicineThe American journal of psychiatry
- 2015
Combined treatment with citalopram and methylphenidate demonstrated an enhanced clinical response profile in mood and well-being, as well as a higher rate of remission, compared with either drug alone.